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What is already known about this subject:  
• α-Lipoic acid is considered an antioxidant compound useful in the treatment of diabetic 
neuropathy. Some studies in murine models and humans have proposed that the α-lipoic 
acid could promote weight loss, but more studies are needed to better characterize the 
appropriate dose.  
• The omega-3 polyunsaturated fatty acids (n-3 PUFAs), principally the eicosapentaenoic 
acid (EPA) and docohexaenoic acid (DHA), are considered anti-inflammatory compounds, 
which can improve cardiovascular health.  
• The efficacy of n-3 PUFAs to increase weight loss in overweight/obese subjects is 
controversial. The major part of the studies evaluating the effects of the n-3 PUFAs in a 
context of an energy-restricted diet have been performed with a combination of DHA and 
EPA.  
 
What this study adds:  
• This study evaluates the potential body weight lowering effects of a high purity EPA and 
α-lipoic acid supplements (alone or in combination) in overweight/obese women following 
an energy-restricted program.   
• The data suggest that α–lipoic acid supplementation at a dose of 300 mg/day combined 
with an energy-restricted diet may be useful to increase the magnitude of body weight and 
fat mass reduction in healthy overweight/obese women. 
• EPA supplementation did not have any additional effect on the reduction of body and fat 
mass, but it prevents the fall of leptin during weight loss, which could help to prevent 
weight regain in weight-reduced subjects. 
 3 
Abstract 
Objective: To evaluate the potential body weight lowering effects of dietary supplementation 
with eicosapentaenoic acid (EPA) and α-lipoic acid separately or combined, in healthy 
overweight/obese women following a hypocaloric diet.  
Design and Methods: This is a short-term double-blind placebo-controlled lasted 10-weeks 
study with parallel design. Of the randomized participants, 97 women received the allocated 
treatment (Control, EPA (1.3 g/d of EPA), α-lipoic acid (0.3 g/d) and EPA+ α-lipoic acid (1.3 
g/d + 0.3 g/d)), finishing 77 volunteers. All groups followed an energy-restricted diet of 30% 
from the total energy expenditure. Body weight, anthropometric measurements, body 
composition, resting energy expenditure, blood pressure, serum glucose, insulin and lipid 
profile, as well as leptin and ghrelin levels, were assessed at baseline and after nutritional 
intervention.  
Results: Body weight loss was significantly higher (P < 0.05) in those groups supplemented 
with α-lipoic acid. EPA supplementation significantly attenuated (P < 0.001) the decrease in 
leptin levels that occurs during weight loss. Body weight loss improved lipid and glucose 
metabolism parameters, but without significant differences between groups. 
Conclusion: The intervention suggests that α-lipoic acid supplementation alone or in 
combination with EPA may help to promote body weight loss in healthy overweight/obese 
women following energy-restricted diets.  
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Introduction 
Obesity is considered as an important public health disease that predisposes people to a 
wide range of other chronic pathologies such as type-2 diabetes, coronary heart disease, 
stroke, obstructive-sleep apnea and certain forms of cancer (1).  
α-Lipoic acid (thioctic acid, 5-(1,2-dithiolan-3-yl) pentanoic acid) is a naturally occurring 
antioxidant and co-factor for mitochondrial enzymes (2). Several studies have suggested 
important anti-obesity properties for α-lipoic acid. Thus, in rodents, α-lipoic acid 
supplementation promotes the reduction of body weight and fat mass (3–5)  by decreasing not 
only food intake, but also by reducing feed efficiency (3) and stimulating energy expenditure 
(6). Furthermore, some trials in overweight, obese and/or diabetic subjects have also 
suggested that supplementation with α-lipoic acid could in some cases promote weight loss, 
reduce fat mass and increase satiety (7,8). However, studies in humans with α-lipoic acid 
supplementation are limited and with controversial outcomes, and it is difficult to reach firm 
conclusions regarding the proper dose and its potential role in the treatment of obesity. 
Although several studies have demonstrated that n-3 polyunsaturated fatty acids (n-3 
PUFAs) could improve cardiovascular health, the use of these fatty acids on obesity treatment 
remains unclear (9). Thus, some studies described that n-3 PUFAs could have positive effects 
on body weight reduction (10,11), whereas others have reported no effects on adiposity 
(12,13). Most of the studies in humans have been performed using a combination of 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), but only few trials have 
evaluated the effects of these n-3 PUFAs separately. Several investigations have suggested 
that EPA and DHA have different hemodynamic properties and actions on cell function 
(14,15). Furthermore, the effects of EPA supplementation in healthy overweight/obese 
subjects on body weight and fat mass loss have been scarcely investigated until now. 
Hence, the aim of this trial was to evaluate the potential body weight lowering effects of 
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dietary supplementation with EPA and α-lipoic acid separately or in combination, in healthy 
overweight/obese women during a hypocaloric diet.  
 
Design and Methods 
Participants 
Women aged 20-50 years were recruited by advertisement in local newspapers and by calls 
for volunteers from the database of the Metabolic Unit (MU) of the University of Navarra. 
The inclusion criteria were: 1) female, 2) regular menstrual cycles, 3) BMI between 27.5 and 
40 Kg/m2, 3) unchanged weight (± 3 Kg) for the last 3 months and 4) all subjects should have 
an overall healthy physical and psychological condition.  
Study design and intervention 
This study was a parallel, short-term randomized double blind placebo-controlled trial 
performed in compliance with the Helsinki Declaration. The trial was approved by the 
Research Ethics Committee of the University of Navarra and registered at clinicaltrials.gov as 
NCT01138774. 
Out of the 103 participants, who gave their signed consent and were assigned by a scientist 
of the MU to one of the four experimental groups by simple randomization using the 
Microsoft Excel Office 2003 Software (Microsoft Inc., USA) that generates random numbers, 
finally 97 women received the allocated treatment, with 77 finishing the trial  (Figure 1). The 
intervention groups varied in the type of daily supplement: 1) Control group: 3 placebo-I 
capsules (containing sunflower oil) and 3 placebo-II capsules (containing same excipients 
than the α-lipoic acid capsules), 2) EPA group: 1300 mg/d of EPA distributed in 3 capsules of 
EPA 80 (provided by Solutex®, Madrid, Spain), containing 433.3 mg of EPA and 13.8 mg of 
DHA as ethyl-ester; and 3 placebo-II capsules, 3) α-lipoic acid group: 300 mg/d of α-lipoic 
acid from 3 capsules containing 100 mg of α-lipoic acid (Nature’s Bounty®, NY, USA), and 3 
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placebo-I capsules; and 4) EPA+ α-lipoic acid group: 1300 mg/d of EPA (distributed in 3 
capsules of EPA 80) and 300 mg/d of α-lipoic acid  (from 3 capsules containing 100 mg of α-
lipoic acid), respectively. Therefore, each daily dose was divided into three equal doses to 
minimize the impact of decline in plasma levels after oral supplementation, and each 
participant consumed a total of 6 capsules per day (2 at breakfast, 2 at lunch and 2 at dinner). 
Both placebo-I (sunflower oil) and EPA capsules were provided by Solutex, and were similar 
in shape and size. Placebo-II capsules were similar in appearance to the α-lipoic acid capsules. 
All intervention groups followed a weight-reduction program consisting of a calorie-
restricted balanced diet (55% carbohydrates; 30% lipids, 15% proteins) in accordance with 
the American Heart Association guidelines, and prescribed individually by a dietitian. During 
the baseline visit, each subject was instructed to follow an energy-restricted diet accounting to 
30% less than her total energy expenditure, and to not change the physical activity pattern 
during the 10-weeks intervention period. Additionally, volunteers were advised to avoid any 
marketed omega-3 supplement and enriched products. 
The main outcome of the study was the amount of weight loss. Follow-up visits were 
scheduled with each volunteer every two weeks to monitor weight, assess the compliance 
with the assigned diet, motivate participants and ensure that all capsules were consumed. 
At baseline and at endpoint the volunteers went under 10-12 h fasting conditions to the 
MU and met with the physician, the dietitian and the nurse. Anthropometric measurements, 
body composition analysis, physical activity, food intake, respiratory exchange measurements 
by indirect calorimetry and blood pressure were evaluated (See Supporting information). A 
catheter was then inserted into the antecubital vein for a fasting blood sample extraction. 
Thereafter, all participants underwent an oral glucose tolerance test (OGTT). In order to 
evaluate the effect of supplementation, biochemical determinations of glucose and lipid 
metabolism as well as of leptin and ghrelin were assessed (See Supporting Information).  
 7 
 
Statistics 
The number of subjects per arm of intervention was estimated at sixteen subjects, which 
would allow a detection of approximately a difference of 5 kg with a dispersion of 5 kg (5 ± 5 
kg) in weight loss between experimental groups, at a 0.05 level of significance, with a 
statistical power of 80%. Since a dropout rate of 25% was expected, the final sample size 
estimation was established in at least 20 participants per group to be recruited. 
A per-protocol analysis was performed including all volunteers for which end-of –
intervention values were available, however, intention-to-treat analysis using the last 
measured reported during at least one follow-up visit was also conducted without relevant 
differences between both analyses (See Supporting Information Table S1). For categorical 
variables, differences were examined by using the chi-square test. Normality was evaluated 
using the Shapiro-Wilk test. Differences were considered significant if P-value <0.05. 
Additionally for secondary outcomes the Benjamini-Hochberg approach (16) was used to 
correct for multiple comparisons in order to counteract the false discovery rate. The 
differences after the nutritional intervention trial within each group were analyzed by 
Student's t test or by Wilcoxon test, depending of the sample distributions. Comparisons at 
baseline and in the effects between the four experimental groups in subjects who completed 
the study were evaluated using the two-way ANOVA. When the differences were statistically 
significant at the interaction level (EPA x α-lipoic acid supplementation), a Student's t test 
was performed to compare the effects of each treatment. Also, some values affected by 
potential confounders were adjusted accordingly. Statistical analysis was performed using 
Stata Statistical Software (Release 12. College Station, TX: StataCorp LP).  
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Results 
Effects on body weight and body composition 
There were no significant differences between the four experimental groups in all subjects 
whom came to the first visit (Supporting Information Table S1). On average, the physical 
activity factor was 1.40 ± 0.08, which corresponds to sedentary activity and was maintained 
during the study period; the rate of capsules intake was 99% in all the groups. In general no 
adverse effects were reported during the trial. 
After the 10 weeks of nutritional intervention, all groups showed significant differences 
(P< 0.05) in the decrease in body weight, as well as in waist and hip circumference and the 
waist to hip ratio (WHR) as compared to baseline (Table 1). Additionally the changes in 
weight loss and anthropometric measurements were accompanied by a significant reduction 
of total fat mass, lean mass, android fat, gynoid fat and the android/gynoid ratio in all the 
intervention groups (Table 1).  Weight loss was also accompanied by a statistically significant 
(P< 0.001) decrease in resting metabolic rate (RMR) in all intervention groups.  
When the differences between groups were evaluated, it was observed that those receiving 
α-lipoic acid supplementation showed a higher statistically significant reduction (P< 0.05) in 
body weight, hip circumference and fat mass comparing to the others at the end of the trial 
(Table 1). This pattern was observed in the α-lipoic acid supplemented groups from the first 
weeks of treatment and became more prominent during the trial (see Figure S1 in Supporting 
Information). Supplementation with EPA did not significantly modify body weight, but 
caused a moderate decrease in the WHR (P< 0.05), even though when the change in WHR 
was adjusted for body weight loss. Interestingly, EPA supplementation was able to partly 
prevent (P< 0.05) the drop in RMR secondary to weight loss.  In the α-lipoic acid 
supplemented groups, the fall in RMR was not significantly different from the RMR changes 
observed in the control group, besides the higher weight loss observed in α-lipoic acid groups 
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(Table 1). Moreover, there were not differences between groups either in changes (Table 1) or 
endpoint values of energy intake (See Supporting Information Figure S2) and the decrease in 
weight loss were not significantly affected by the changes in energy intake (R2= 0.007 P= 
0.48).  
Effects on lipid and glucose metabolism profile 
After the 10 weeks of nutritional intervention, the groups supplemented with EPA showed 
a significant increase (P < 0.05) in the β-hydroxybutyrate levels, even after adjusting by body 
weight loss (Table 2). Serum levels of total cholesterol were significantly (P< 0.05) reduced 
in all experimental groups, while the LDL-cholesterol only decrease significantly (P< 0.05) in 
the groups with EPA. Furthermore, there was a statistically significant drop, compared with 
baseline levels, in triglycerides (P< 0.01) and diastolic blood pressure (DBP) (P< 0.05) in the 
group supplemented with EPA+ α-lipoic acid. Besides, no significant differences were found 
between groups for any of these variables (See Supporting Information Table S2).  
Levels of fasting glucose were reduced in the four experimental groups at the end of the 
trial as compared with baseline, although statistically significant decreases (P< 0.01) were 
only displayed in the Control and EPA+ α-lipoic acid groups. Furthermore, insulin levels as 
well as the HOMA-IR were also significantly reduced at the endpoint in Control and in both 
groups supplemented with α-lipoic acid (Table 2). However, when the differences between 
groups were evaluated, no significant changes were obtained, although a significant 
interaction between supplements (P< 0.01) was observed (Table 2).  
The data of the OGTT revealed that the EPA+ α-lipoic acid group had the major changes 
in glucose during the OGTT (Figure 2a), but without significant modifications at the end of 
the nutritional intervention in the glucose incremental area under curve (iAUC) (Figure 2b). 
Although all groups, excepting, the group supplemented with EPA, appears to improve the 
changes in insulin during the OGTT (Figure 2c), no significant differences were found 
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between groups in the insulin iAUC (Figure 2d). 
Effects on leptin and ghrelin levels  
After the nutritional intervention, a significant (P< 0.01) reduction in leptin levels was 
demonstrated in almost all groups, except in the EPA supplemented group (Table 2). Thus, 
the groups supplemented with α-lipoic acid showed an important drop in leptin in parallel 
with the reduction of fat mass. Interestingly, the groups with EPA supplementation showed a 
significantly lower decline (P< 0.001) in leptin levels with respect to the others (Table 2); also 
it was observed that the changes in leptin had a positive significant association with the RMR 
modifications (r = 0.42, P< 0.001).  The EPA + α-lipoic acid group showed a statistically 
significant (P< 0.05) increase in ghrelin at the end of the trial, but without differences 
between groups (Table 2).  
Adjustment for multiple comparisons 
In order to control the false discovery rate and give more forcefulness to the results, the 
Benjamini-Hochberg adjustment for multiple comparisons was used, finding that in the 
secondary outcomes, only the change in leptin remains significantly different between groups 
(Tables 1 and 2).  
 
Discussion 
In this study we found that the supplementation with α-lipoic acid (alone or in combination 
with EPA) at lower doses (300 mg/day) could help to promote weight loss and fat mass 
reduction in healthy overweight/obese women following an energy-restricted balanced diet. In 
this context, Koh et al. (8) found that α-lipoic acid supplementation (1200-1800 mg/day) 
together with a calorie restricted diet in Asian overweight and obese subjects promotes weight 
loss as well as BMI and waist circumference reduction in a dose-dependent manner, but this 
effect was only significant at the highest dose tested. Carbonelli et al. (7) described how 
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supplementation with α-lipoic acid (800 mg/day) promotes the reduction of weight, fat mass 
and waist circumference only in overweight and obese Caucasian subjects, but not in normal-
weight subjects, suggesting that these effects could be due to the increased satiety induced by 
α-lipoic acid. Besides the positive effects on weight loss observed in some trials, the anti-
obesity properties of α-lipoic acid in humans remain controversial. Thus, other studies in 
overweight and obese subjects with impaired glucose tolerance or type-2 diabetes, following a 
regular diet, have observed no effect on anthropometric measurements after supplementation 
with α-lipoic acid (17,18). Thereby, the discrepancies between the different trials could be 
related to the specific features of the subjects, the diet assigned and the duration of the trials. 
Studies in animal models have suggested that α-lipoic acid could promote weight loss by 
reducing food intake and stimulating energy expenditure (3,19). However, our current data do 
not support a role of increased satiety for α-lipoic acid at the dose used in this trial, since 
differences in energy intake were not detected. Moreover, our data suggest that the RMR 
changes are not differentially affected by α-lipoic acid supplementation, since after adjusting 
for body weight loss, the RMR decrease in the α-lipoic acid groups was similar to control 
group. Adipose tissue is a target organ whereby α-lipoic acid exerts its anti-adiposity effects 
by inhibiting lipogenesis (20), increasing lipolysis (21) and inhibiting adipogenesis (2). 
Therefore these mechanisms could be also contributing to the body and fat mass lowering 
actions of α-lipoic acid, without necessarily involving an increment of energy expenditure. 
Studies evaluating the effects of n-3 PUFAs on weight loss in obese humans have reported 
contradictory outcomes (10,22,23), which largely depend on the different amounts and ratios 
of n-3 PUFAs type (EPA or DHA), as well as the phenotypical characteristics of the recruited 
subjects. Most of the studies analyzing the effects of n-3 PUFAs have used supplements that 
include both EPA and DHA. In fact, several studies have suggested that EPA and DHA have 
different effects on adipocyte function (24). In agreement with the present study, Itoh et al. 
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(22), who used highly purified (>98%) EPA in obese subjects, showed that supplementation 
with this n-3 PUFA (1.8 g/day) for 3 months had no effects on waist circumference reduction 
and BMI loss.  
A remarkable finding of the present trial was the fact that the reduction of leptin secondary 
to fat mass loss was significantly lower in the group supplemented with EPA. In accordance 
with this, in vitro and in vivo studies have evidenced the ability of EPA in stimulating the 
production of leptin in rodents (25,26). In this context, Hinkle et al. (27) have suggested that 
the decrease of leptin during weight loss could contribute to hunger, a lowered metabolic rate, 
and further weight regain; therefore, leptin replacement therapy could prevent subsequent 
RMR fall after weight loss and the weight regain in weight-reduced subjects. Moreover, the 
positive and significant association between RMR and leptin could suggest that the less drop 
in the RMR found in the EPA treated groups can be related with the effect of EPA on leptin. 
In this regard, Doucet et al. (28) have proposed that after weight loss, the decrease in RMR 
adjusted by fat mass and fat free mass, is explained mainly by changes in circulating plasma 
leptin. Although EPA supplementation did not promote weight loss, its actions on leptin seem 
to suggest that supplementation with this fatty acid could become important for weight loss 
maintenance. Few studies have addressed the beneficial effects of n3-PUFAs on weight 
maintenance after a weight loss program, and no significant effects have been described 
(13,23). However, it has been suggested that the effects of n3-PUFAs could be evident after a 
long time period and that their accumulation in the body could contribute to weight 
management (23,29).  
The changes noted in serum metabolic profile in this study clearly confirm the benefits of 
weight loss and fat mass reduction by an energy-restricted diet on several metabolic 
alterations associated with the harmful effects of obesity, as previously demonstrated (30). 
The effects of the n-3 PUFAs on glucose and lipid profile are not consistent, depending 
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mainly on the baseline metabolic characteristics. The main outcome observed in the studies 
with n-3 PUFAs in overweight/obese subjects is the reduction in triglyceride levels (23,31), 
however, the doses used in these trials range between 1.6 and 4 g per day, and are therefore 
higher than the dose used in this study (1.3 g/day). Furthermore, the effects of n-3 PUFAs on 
the cholesterol profile are not clear (32–35). Similar to our observations, other trials have 
described that the levels of LDL-cholesterol, HDL-cholesterol and total-cholesterol remain 
unchanged after n-3 PUFAs treatment (12,23,31). Although the increase in β-hydroxybutyrate 
levels was not significantly different between groups after the Benjamini-Hochberg 
correction, it cannot be discarded some effect of EPA in fatty acid oxidation, as has been 
previously reported in other studies in both humans (10) and rodents (36). 
Several studies in type 2 diabetic and impaired glucose tolerance subjects have exhibited 
the properties of α-lipoic acid to ameliorate glucose metabolic complications (17,37). 
Furthermore, studies analyzing the effects of n-3 PUFAs in glucose metabolism have reached 
contradictory outcomes (12,38,39). In the current study, a significant interaction between both 
supplements in glucose concentration changes was found; however, it is important to note, 
that the major decreases found in glucose and HOMA-IR in the control and EPA+α-lipoic 
acid group, may have been conditioned by the higher levels at baseline in these groups on 
insulin levels. Though, the effects of supplementation are influenced possibly by the 
metabolic status at baseline, it could be interesting to further evaluate the possible coadjuvant 
properties of n-3 PUFAs and α-lipoic acid on glucose metabolism. 
The safety and toxicity of the α–lipoic acid have been tested by several authors at different 
doses and times, being the greatest dose administered 2400 mg/day during a 2 years period 
(40) with no reported adverse effects versus placebo. The dose used in our study is much 
lower than the dose considered safe.  
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On the other hand, it is important to take into account the limitations of this study, 
including the sample size, the short duration of the nutritional intervention, the lack of a 
maintenance weight loss period, the absence of blood samples of some volunteers and 
especially the fact that the outcomes could have been conditioned by the degree of adherence 
to the hypocaloric diet. Thus, the findings of our trial suggest the importance of performing 
longer randomized controlled trials followed by sustained weight maintenance periods.  
In summary, our data suggest that α–lipoic acid supplementation at a dose of 300 mg/day 
combined with an energy-restricted diet might help to promote weight loss and fat mass 
reduction in healthy obese women. Although EPA supplementation did not have any 
additional effect on the reduction of body and fat mass, it prevents the fall of leptin during 
weight loss. It is essential that these observations be further explored and the underlying 
mechanisms better elucidated. 
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